BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32979109)

  • 21. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations.
    Horn H; Staiger AM; Vöhringer M; Hay U; Campo E; Rosenwald A; Ott G; Ott MM
    Am J Surg Pathol; 2015 Jan; 39(1):61-6. PubMed ID: 25229766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.
    Han YB; Yang JM; Kwon HJ; Lee JO; Lee JS; Paik JH
    Anticancer Res; 2021 Nov; 41(11):5677-5692. PubMed ID: 34732441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
    Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
    J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
    Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study.
    Khan UT; Kelly M; Dodd J; Fergiani S; Hammer B; Smith J; Arumainathan A; Atherton M; Carter A; Racu-Amoasii I; Kalakonda N; Pettitt A; Menon G
    J Clin Pathol; 2021 Dec; 74(12):816-818. PubMed ID: 33380460
    [No Abstract]   [Full Text] [Related]  

  • 28. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.
    Marino FZ; Aquino G; Brunelli M; Scognamiglio G; Pedron S; Ronchi A; Cozzolino I; Sparano L; Botti G; Panico L; De Chiara A; Franco R;
    Virchows Arch; 2021 Sep; 479(3):565-573. PubMed ID: 33768318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.
    Suzuki M; Muroi A; Nojima M; Numata A; Takasaki H; Sakai R; Yokose T; Miyagi Y; Koshikawa N
    Proteomics Clin Appl; 2020 Jan; 14(1):e1900091. PubMed ID: 31721454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.
    Ichikawa K; Aritaka N; Ogura K; Hosone M; Ota Y; Sato E; Komatsu N; Hirano T
    Int J Clin Exp Pathol; 2015; 8(6):7559-64. PubMed ID: 26261669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients.
    Li Y; Gupta G; Molofsky A; Xie Y; Shihabi N; McCormick J; Jaffe ES
    Am J Surg Pathol; 2018 Feb; 42(2):269-276. PubMed ID: 29112016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
    Naseem M; Asif M; Khadim MT; Ud-Din H; Jamal S; Shoaib I
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1103-1107. PubMed ID: 32334477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas.
    Otto C; Scholtysik R; Schmitz R; Kreuz M; Becher C; Hummel M; Rosenwald A; Trümper L; Klapper W; Siebert R; Küppers R;
    Genes Chromosomes Cancer; 2016 Dec; 55(12):932-943. PubMed ID: 27356265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Richter transformation with c-MYC overexpression: report of three cases.
    Wang L; Aghel A; Peterson B; Wang-Rodriguez J; Wang HY; Zhao XF
    Int J Clin Exp Pathol; 2015; 8(6):7540-6. PubMed ID: 26261666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.
    Son SM; Ha SY; Yoo HY; Oh D; Kim SJ; Kim WS; Ko YH
    Mod Pathol; 2017 Jan; 30(1):4-14. PubMed ID: 27687005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.